Your Daily Psychedelics & Therapy Briefing
Psilocybin, MDMA-assisted therapy, clinical trials, and the regulated psychedelic medicine movement. Get the latest psychedelics & therapy developments delivered to your inbox every morning. AI-powered, personalized, and grounded in real sources.
Louisiana Advances Pilot Program, New Clinical Data Shows Promise for Psilocybin and LSD
Louisiana lawmakers have passed a bill to establish a psychedelic-assisted therapy pilot program, which will be funded by opioid settlement dollars. The legislation, which includes psilocybin, ibogaine, and MDMA, received unanimous approval in both the Senate (35-0) and House of Representatives (97-0) and now awaits the governor's signature. This initiative aims to explore alternative treatments for opioid use disorders, co-occurring substance use disorders, and treatment-resistant mental health conditions.
Compass Pathways presented late-breaking Phase 3 data for its COMP360 psilocybin in treatment-resistant depression (TRD) at the 2026 American Society for Clinical Psychopharmacology (ASCP) Annual Meeting. The results from two trials (COMP005 and COMP006) demonstrated "highly statistically significant and clinically meaningful improvements" in Montgomery-Åsberg Depression Rating Scale (MADRS) scores, with COMP360 being the first classic psychedelic to consistently achieve such positive outcomes. Compass Pathways plans to engage with the FDA regarding a New Drug Application (NDA) submission.
Definium Therapeutics also shared detailed adverse event and Phase 2b efficacy data for its DT-120, a pharmaceutically optimized formulation of lysergic acid diethylamide (LSD), for generalized anxiety disorder (GAD) at the ASCP meeting. A single dose of DT-120 showed a 7.7-point separation from placebo on a GAD measure, with 48% of participants experiencing full clinical remission at 12 weeks post-dose.
The Bottom Line
State-level legislative action, particularly the innovative use of opioid settlement funds in Louisiana, combined with promising new Phase 3 and Phase 2b clinical trial data for psilocybin and LSD, signals a continued acceleration in the development and acceptance of psychedelic-assisted therapies for a range of mental health conditions. These developments underscore a growing momentum towards integrating these novel treatments into mainstream psychiatric care.
Get Psychedelics & Therapy in your inbox every morning
Join readers who start their day with an AI-powered briefing on psychedelics & therapy and the topics they care about most — fully sourced and ready in 5 minutes.
Start your free trial7-day free trial · No credit card required
Related Briefings
Mental Health
Therapy research, workplace wellness, anxiety and depression treatments, and destigmatization efforts.
Pharmaceuticals
Drug approvals, clinical trials, pricing debates, and the pharmaceutical industry landscape.
Biotechnology
Gene editing, drug development, clinical trials, and the science of engineering biology.
Pick your topics
Psychedelics & Therapy, plus anything else you follow
We research overnight
AI synthesizes real-time sources while you sleep
Read in 5 minutes
Cited, structured, no fluff — in your inbox every morning